Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > DCs and NK cells as the enhancer of OVs
View:
Post by Noteable on Jan 12, 2023 4:02pm

DCs and NK cells as the enhancer of OVs

January 10, 2023 - "... efforts are being undertaken to prevent the immunosuppression that is linked with tumors. Anti-cancer treatment based on oncolytic viruses is one of the most fascinating therapeutic techniques for addressing such challenges (oncotherapy). OVs selectively target and destroy cancer cells through direct oncolysis and antitumor immunity (115).

Immunosuppression inside the tumor microenvironment (TME) provides an environment that is susceptible to infection and is permissive to viral multiplication, in the end, this leads to death of cancer cells. Upon OV-induced immunogenic cancer cell death and the subsequent "danger" signals, there is an increase in APC and lymphocyte infiltration in the TME.

This rise in APC and lymphocyte infiltration leads to the stimulation of nonspecific and specific anti-tumor response, reducing the risk of cancer recurrence over the long term (
116). OVs are also responsible for the activation of additional immune responses, which serve to counterbalance the decrease in the presentation of tumor antigens and to boost the interaction of APCs with T cells that are specific to the tumor ..."


https://www.frontiersin.org/articles/10.3389/fimmu.2022.950079/full
Comment by Noteable on Jan 12, 2023 4:19pm
"... OVs have the advantage of “warming up” immunologically cold tumors to the level of an immunologically activated malignancy ..." "... Additionally, it has been discovered that by encouraging dendritic cell maturation and the polarization of macrophages to the M1 phenotype, the OV@NK system can alleviate immunosuppression in the TME. Both in vitro and in vivo ...more  
Comment by TitanBrawler on Jan 12, 2023 7:29pm
Great news .. maybe will get a 60 billion dollar buyout soon. Lol
Comment by Buckhenry on Jan 12, 2023 8:34pm
that's toooo low man... with the posts of unnoteable and his baby pumpers following i expect no less than 100B.    they got the inside track and have a direct line to Matt. 
Comment by Noteable on Jan 28, 2023 4:24pm
Dendretic cells (DC) and T-cells (NK cells) are an effective way of delivering ONCY's pelareorep (reovirus) to the patient through intravenous administration.
Comment by TMAZZ21 on Jan 28, 2023 4:44pm
Noteable, curious to know how many shares do you own? You must be heavily invested, there's no way your spending this much time posting and not be heavily invested! Let's hope your right and this dream becomes a reality! :)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities